Slingshot members are tracking this event:

Theravance Biopharma (TBPH) announces new developmental partnership with Celgene (CELG) for TD-6450, its multivalent NS5A inhibitor

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
TBPH Community voting in process
CELG Community voting in process

Additional Information

Additional Relevant Details The author of the article is long on TBPH
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 28, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2a, Phase 2 Clinical Trial, Td-6450, Hepatitis C, Partnership